Research Analysts Offer Predictions for MOLN FY2025 Earnings

Molecular Partners AG Sponsored ADR (NASDAQ:MOLN) – Equities research analysts at HC Wainwright issued their FY2025 earnings estimates for Molecular Partners in a research report issued to clients and investors on Tuesday, January 27th. HC Wainwright analyst R. Burns anticipates that the company will earn ($2.10) per share for the year. HC Wainwright has a “Buy” rating and a $13.00 price target on the stock. The consensus estimate for Molecular Partners’ current full-year earnings is ($1.93) per share. HC Wainwright also issued estimates for Molecular Partners’ Q4 2025 earnings at ($0.40) EPS.

A number of other equities research analysts also recently weighed in on MOLN. JPMorgan Chase & Co. cut their target price on Molecular Partners from $4.00 to $3.75 and set a “neutral” rating for the company in a research report on Monday, December 8th. Weiss Ratings restated a “sell (d-)” rating on shares of Molecular Partners in a report on Monday, December 22nd. Two investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Molecular Partners presently has an average rating of “Hold” and an average target price of $9.58.

Molecular Partners Price Performance

Molecular Partners stock opened at $4.26 on Thursday. Molecular Partners has a 12-month low of $3.36 and a 12-month high of $5.35. The stock has a market capitalization of $172.02 million, a PE ratio of -2.22 and a beta of 1.07. The firm has a 50 day simple moving average of $4.24 and a 200-day simple moving average of $3.94.

Molecular Partners (NASDAQ:MOLN) last released its earnings results on Thursday, October 30th. The company reported ($0.41) EPS for the quarter, beating the consensus estimate of ($0.46) by $0.05.

Key Molecular Partners News

Here are the key news stories impacting Molecular Partners this week:

• Positive Sentiment: HC Wainwright initiated coverage with a “Buy”/”Strong‑Buy” and a $13 price target (≈205% upside vs. current price), giving investors a clear upside thesis that likely boosted the shares. The Fly
• Positive Sentiment: Analyst R. Burns from HC Wainwright flagged an improving EPS trajectory over 2025–2027 (FY2026 and FY2027 estimates are less negative than FY2025), supporting a recovery narrative despite ongoing losses. MarketBeat
• Neutral Sentiment: HC Wainwright published detailed quarter‑by‑quarter EPS forecasts for 2026–2027 (examples: Q1‑2026 $(0.41), Q2‑2026 $(0.43), Q3‑2026 $(0.43), Q4‑2026 $(0.44)), giving investors a multi‑year model to benchmark execution and cash‑burn expectations. MarketBeat
• Negative Sentiment: Despite the bullish rating, HC Wainwright still projects material net losses (FY2025 $(2.10) per share — worse than the consensus $(1.93)), underscoring that valuation depends on pipeline progress and execution rather than near‑term profitability. MarketBeat

About Molecular Partners

Molecular Partners AG is a clinical-stage biopharmaceutical company headquartered in Zurich, Switzerland, specializing in the design and development of DARPin® (Designed Ankyrin Repeat Protein) therapies. These small, modular proteins are engineered to bind with high specificity and affinity to disease-relevant targets. The company’s technology platform aims to deliver novel treatments across multiple therapeutic areas by leveraging the unique properties of DARPins, including stability, tissue penetration and multi-specific binding capabilities.

The company’s development pipeline spans infectious diseases, ophthalmology and oncology.